Retatrutide vs Semaglutide vs Tirzepatide – Incretin Landscape Overview
High-Level Comparison (Conceptual)
- Semaglutide: GLP-1 receptor agonist; robust evidence for glycemic control and weight loss.
- Tirzepatide: Dual GIP/GLP-1 agonist; enhances metabolic effects beyond GLP-1 alone.
- Retatrutide: Triple GIP/GLP-1/glucagon agonist; investigational, with strong early weight-loss and metabolic signals under study.
Key Takeaways
- Retatrutide targets broader physiology; it is not yet established how this will translate into long-term outcomes vs approved agents.
- Only approved agents should be used in clinical practice; retatrutide remains in the research domain.
- Confusion around “GLP3 shots” or “Triple G” highlights the need for high-quality education, which this hub provides.
For investigational-only context, start at the
GLP3 Retatrutide Hub.
